Patents by Inventor Fiona A. Harding

Fiona A. Harding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for identifying antibodies with reduced immunogenicity
    Patent number: 9279016
    Abstract: The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-TNF-? antibody having reduced immunogenicity as compared to the reference anti-TNF-? reference antibody.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: March 8, 2016
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Olivia Jennifer Razo
  • Anti-VEGF antibodies and their uses
    Patent number: 9079953
    Abstract: The present disclosure relates to antibodies directed to vascular endothelial growth factor (“VEGF”) and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: July 14, 2015
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. DuBridge, David B. Powers
  • PROTEASES PRODUCING AN ALTERED IMMUNOLOGICAL RESPONSE AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20150152404
    Abstract: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.
    Type: Application
    Filed: January 9, 2015
    Publication date: June 4, 2015
    Inventors: David A. Estell, Fiona A. Harding, Ayrookaran J. Poulose
  • Anti-HER2 antibodies and their uses
    Patent number: 8937159
    Abstract: The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: January 20, 2015
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20150010538
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 8, 2015
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING
  • ANTI-CD25 ANTIBODIES AND THEIR USES
    Publication number: 20150010539
    Abstract: The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 8, 2015
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: YOSHIKO AKAMATSU, FIONA A. HARDING, PAUL R. HINTON, MENGLI XIONG, OLIVIA JENNIFER RAZO, SHIMING YE
  • FC VARIANTS
    Publication number: 20140377253
    Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 25, 2014
    Applicant: ABBVIE BIOTHERAPEUTICS INC.
    Inventors: Fiona A. HARDING, Paul R. HINTON, Mengli XIONG, Olivia Jennifer RAZO, Shiming YE
  • Perhydrolase epitopes
    Patent number: 8871722
    Abstract: The present invention provides perhydrolase enzyme CD4+ T-cell epitopes, as well as variants that exhibit reduced immunogenic responses, as compared to the parental perhydrolase. The present invention further provides DNA molecules that encode perhydrolase variants, and host cells comprising DNA encoding perhydrolase variants, as well as methods for making perhydrolase enzymes less immunogenic. In addition, the present invention provides various compositions that comprise perhydrolase variants that are less immunogenic than the wild-type perhydrolase. In some specific embodiments, the present invention provides perhydrolase variants with reduced immunogenicity identified and/or characterized using the methods of the present invention. These enzymes find use in cleaning and other applications. In some preferred embodiments, the present invention finds particular use in applications involving cleaning, bleaching and disinfecting.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: October 28, 2014
    Assignee: Danisco US Inc.
    Inventor: Fiona A. Harding
  • PROTEASES PRODUCING AN ALTERED IMMUNOLOGICAL RESPONSE AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20140294881
    Abstract: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.
    Type: Application
    Filed: September 18, 2008
    Publication date: October 2, 2014
    Applicant: Danisco US Inc.
    Inventors: David A. Estell, Fiona A. Harding, Ayrookaran J. Poulose
  • METHODS FOR IDENTIFYING ANTIBODIES WITH REDUCED IMMUNOGENICITY
    Publication number: 20140227251
    Abstract: The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-TNF-? antibody having reduced immunogenicity as compared to the reference anti-TNF-? reference antibody.
    Type: Application
    Filed: September 18, 2013
    Publication date: August 14, 2014
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. HARDING, Olivia Jennifer Razo
  • ANTI-TNF-ALPHA ANTIBODIES AND THEIR USES
    Publication number: 20140212424
    Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.
    Type: Application
    Filed: February 28, 2014
    Publication date: July 31, 2014
    Applicant: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
  • PROTEASES PRODUCING AN ALTERED IMMUNOGENIC RESPONSE AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20140186922
    Abstract: The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 3, 2014
    Applicant: Danisco US Inc.
    Inventors: David A. Estell, Fiona A. Harding
  • CAB molecules
    Patent number: 8728470
    Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: May 20, 2014
    Assignee: Danisco US Inc.
    Inventors: Judith A. Fox, Fiona A. Harding, Rashid M. Harunur, Volker Schellenberger
  • Anti-TNF-? antibodies and their uses
    Patent number: 8722860
    Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: May 13, 2014
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
  • Cd4+ epitopes of bone morphogenetic proteins
    Patent number: 8501424
    Abstract: The present invention provides CD4+ T-cell epitopes in bone morphogenetic proteins (BMPs). In particular embodiments, the present invention provides CD4+ T-cell epitopes of BMP-7 and BMP-14. In some preferred embodiments, the present invention provides CD4+ T-cell epitopes of BMP-7 and BMP-14 that are suitable for modification to reduce the immunogenicity of the BMP-7 and BMP-14 proteins.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: August 6, 2013
    Assignee: Danisco US Inc.
    Inventor: Fiona A. Harding
  • ANTI-TNF-a ANTIBODIES AND THEIR USES
    Publication number: 20120135005
    Abstract: The present disclosure relates to antibodies directed to the tumor necrosis factor alpha (“TNF-?”) and uses of such antibodies, for example, to treat diseases associated with the activity and/or overproduction of TNF-?.
    Type: Application
    Filed: April 16, 2010
    Publication date: May 31, 2012
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers
  • CAB MOLECULES
    Publication number: 20120107314
    Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.
    Type: Application
    Filed: November 2, 2011
    Publication date: May 3, 2012
    Inventors: Judith A. Fox, Fiona A. Harding, Rashid M. Harunur, Volker Schellenberger
  • CAB molecules
    Patent number: 8088609
    Abstract: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.
    Type: Grant
    Filed: April 12, 2005
    Date of Patent: January 3, 2012
    Assignee: Danisco US Inc.
    Inventors: Judith A. Fox, Fiona A. Harding, Rashid M. Harunur, Volker Schellenberger
  • Cytokines and Cytokine Receptors with Reduced Immunogenicity
    Publication number: 20110263517
    Abstract: The present invention provides methods for the identification of CD4+ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no longer capable of initiating the CD4+ T-cell response. In some embodiments, the present invention provides means and compositions suitable for reducing the immunogenicity of cytokines and cytokines receptors such as interferon-?, soluble tumor necrosis factor receptor-1, erythoropoietin, and thrombopoietin.
    Type: Application
    Filed: December 1, 2010
    Publication date: October 27, 2011
    Applicant: DANISCO US, INC.
    Inventors: Scott D. Power, Fiona A. Harding
  • ANTI-HER2 ANTIBODIES AND THEIR USES
    Publication number: 20110177095
    Abstract: The present disclosure relates to antibodies directed to HER2 and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of HER2.
    Type: Application
    Filed: December 15, 2010
    Publication date: July 21, 2011
    Applicant: Abbott Biotherapeutics Corporation
    Inventors: Fiona A. Harding, Yoshiko Akamatsu, Robert B. Dubridge, David B. Powers